Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 12/20 | 0.90 |
| ▸ | CCND1 | P24385 | 12/20 | 0.90 |
| ▸ | CDK11A | Q9UQ88 | 11/20 | 0.70 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.70 |
| ▸ | CDK9 | P50750 | 11/20 | 0.70 |
| ▸ | CDK6 | Q00534 | 10/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.62 |
| ▸ | LTK | P29376 | 1/20 | 0.62 |
| ▸ | CLK2 | P49760 | 1/20 | 0.62 |
| ▸ | GSK3A | P49840 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | CDK7 | P50613 | 1/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742917 | 0.95 | CDK4 (1.00) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL30101624 | 0.95 | CDK4 (1.00) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5742570 | 0.93 | CDK4 (0.93) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5741989 | 0.91 | CDK4 (0.75) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5742808 | 0.91 | CDK4 (0.74) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5741919 | 0.89 | CDK4 (0.71) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5743064 | 0.88 | CDK4 (0.70) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL4337293 | 0.87 | CDK4 (0.70) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5742113 | 0.87 | CDK4 (0.70) | CDK4CCND1CDK11ACCNT1CDK9 | |
| SCHEMBL5744196 | 0.87 | CDK4 (0.70) | CDK4CCND1CDK11ACCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094896-B2 | Diaminothiazoles having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-08-22 | — | — | US | claimed |
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | claimed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | claimed |
| US-7105670-B2 | Intermediates useful in the preparation of diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7094896-B2 | Diaminothiazoles having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 34/4885CDK11A 35/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 34/4885CDK11A 35/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 39/4885CDK11A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.